Literature DB >> 34210191

Simulation-Based Evaluation of Dose Titration Algorithms for U-500R Insulin by Pump in Subjects with Type 2 Diabetes.

Xiaosu Ma1, Timothy Waterhouse1, Liza L Ilag1, Trang Ly2, Rattan Juneja1, Parag Garhyan1, Thomas Hardy1, Robert C Hood3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34210191      PMCID: PMC8442177          DOI: 10.1177/19322968211026626

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


× No keyword cloud information.
  4 in total

1.  Simulation-Based Evaluation of Dose-Titration Algorithms for Rapid-Acting Insulin in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antihyperglycemic Medications.

Authors:  Xiaosu Ma; Jenny Y Chien; Jennal Johnson; James Malone; Vikram Sinha
Journal:  Diabetes Technol Ther       Date:  2017-07-12       Impact factor: 6.118

2.  TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL.

Authors:  Robert C Hood; Richard F Arakaki; Carol Wysham; Ying G Li; Julie A Settles; Jeffrey A Jackson
Journal:  Endocr Pract       Date:  2015-03-26       Impact factor: 3.443

3.  Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force.

Authors:  George Grunberger; Jill M Abelseth; Timothy S Bailey; Bruce W Bode; Yehuda Handelsman; Richard Hellman; Lois Jovanovič; Wendy S Lane; Philip Raskin; William V Tamborlane; Caitlin Rothermel
Journal:  Endocr Pract       Date:  2014-05       Impact factor: 3.443

4.  Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study.

Authors:  George Grunberger; Anuj Bhargava; Trang Ly; Howard Zisser; Liza L Ilag; James Malone; Ludi Fan; Shuyu Zhang; Jennal Johnson
Journal:  Diabetes Obes Metab       Date:  2020-01-26       Impact factor: 6.577

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.